Skip to main content

Table 1 SELDI-TOF MS protein peaks differentially expressed in paired sera from SJIA before and after therapy

From: Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy

  Before/after conventional therapy Before/after MRA
Mass (m/z) P Patients with visually distinct peaks/total no. of patients P Patients with visually distinct peaks/total no. of patients
4504 0.0001   0.005  
4758 0.0005   0.0006  
5739 0.0001   0.00000008  
6441 0.00009   0.0001  
6947 0.0005   0.003  
9510 0.0007 6/8 0.00001 12/15
9725 0.00006   0.00001  
11405 0.00001 8/8 0.000000003 14/15
11520 0.000007 8/8 0.000000001 14/15
11641 0.000005 8/8 0.0000000001 14/15
11718 0.0004   0.00002  
11880 0.0002   0.0000006  
12703 0.0006 7/8 0.04 6/15
20816 0.0002 7/8 0.01 9/15
22389 0.0002   0.00005  
23627 0.0002   0.09  
28734 0.0002   0.00006  
33457 0.00001 6/8 0.00001 11/15
66637 0.0001 7/8 0.000009 11/15
74886 0.0006   0.00003  
75622 0.0009   0.0001  
76319 0.0008   0.00002  
79216 0.0007   0.000003  
  1. Differences between mass spectra of sera before and after conventional therapy. Sera from eight patients with SJIA who responded to conventional therapy were analyzed before and after therapy by SELDI-TOF MS using Ciphergen IMAC-3 copper chips. All samples were run in duplicate. Only variables with nonparametric P values of <0.001 are given. Of 282 spectral peaks identified, the 23 listed here had mean signal intensities significantly different (P < 0.001) before and after response to treatment. Proteins are listed according to mass/charge ratio. Visually distinct peaks (in bold type) refers to peaks that were clearly different between paired samples from before and after treatment upon visual inspection of the profiles, as shown in Fig. 1. The numbers of patients in whom these peaks were visually distinct are shown in columns 3 and 5. These peaks represent potential biomarkers of active disease. IMAC-3, immobilized metal affinity capture; MRA, humanized anti-IL-6 receptor monoclonal antibody; SELDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry; SJIA, systemic juvenile idiopathic arthritis.